USE OF MHC CLASS II LIGAND, AS A LAG-3 OR DERIVATIVE, MUTANT FORM OR SOLUBLE FRAGMENT LAG-3, FOR PREPARATION OF IMMUNOTHERAPEUTIC MEDICAMENT

摘要

1. The use of a MHC class II ligand, able to intensify an antigen specific immune response, in combination with an adjuvant-like agent for the manufacture of a medicament for preventing or treating pathological conditions concerned with induction and intensification of an antigen specific immune response, where MHC class II ligand is LAG-3 or a derivative, mutant form or soluble fragment LAG-3, prepared as mentioned in description. 2. The use according to claim 1, wherein the said an antigen specific immune response is T-cell mediated immune response. 3. The use according to claim 2, wherein T-cell mediated immune response is mediated by CD8* T-cells. 4. The use according to claim 3, wherein the conditions concerned with CD8* T-cell mediated immune response is an infectious disease. 5. The use according to claim 4, wherein the infectious diseases are viral, parasitic or bacterial diseases. 6. The use according to claim 1, wherein the said medicament is use for treating of cancerous growth. 7. The use according to any of claims 1-6, wherein the soluble fragments LAG-3 are selected from group, consisting of D1-D2, D1-D4 and LAG-3 fragments. 8. The use according to claim 1, wherein the said medicament is use for anti-cancer immunotherapy.